in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient time period [of time] to inhibit coagulation so as to thereby treat the ischemic disorder in the subject.--

--30. (Amended) The method of claim 29, wherein the sufficient amount ~~comprises~~ from about 75 μg/kg to about 550 μg/kg.--

--31. (Amended) The method of claim 29, wherein the sufficient amount comprises 300 μg/kg.--

--33. (Amended) The method of claim 32, wherein the pharmaceutically acceptable carrier comprises an aerosol, intravenous, oral or topical carrier.--

REMARKS

Claims 1-45 were pending in the subject application. Applicants have hereinabove amended claims 29, 30, 31 and 33. Accordingly, claims 1-45 are pending.

Support for amended claims 29, 30, 31 and 33 may be found, *inter alia*, in originally-filed claims 29-37 on page 116.

Applicants contend that this amendment does not involve an issue of new matter. Accordingly, applicants respectfully request that the Examiner enter this amendment.

In the May 5, 1997 Office Action, the Examiner alleged that restriction is required to one of the the following allegedly independent and distinct inventions under 35 U.S.C. § 121: